Iovance Biotherapeutics (IOVA) Misses Q4 EPS by 2c

Iovance Biotherapeutics (NASDAQ: IOVA) reported Q4 EPS of ($0.45), $0.02 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $480 thousand versus the consensus estimate of $1.44 million.

For earnings history and earnings-related data on Iovance Biotherapeutics (IOVA) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Bio-key International, Inc. (BKYI) Tops Q2 EPS by 24c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c